Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Kanerva

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Molecular Therapy Oncolytics|January 26, 2023
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumorsSaru Basnet, Joao M Santos, Dafne C A Quixabeira, et al.
Frontiers in Immunology|August 9, 2021
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1Victor Cervera-Carrascon, Dafne C A Quixabeira, Joao M Santos, et al.
International Journal of Cancer|August 13, 2009
Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiationMaria Rajecki, Taija af Hällström, Tanja Hakkarainen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumorsPetri Nokisalmi, Sari Pesonen, Sophie Escutenaire, et al.
British Journal of Cancer|December 8, 2022
Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinomaAstrid Murumägi, Daniela Ungureanu, Suleiman Khan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 16, 2011
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirusVincenzo Cerullo, Iulia Diaconu, Lotta Kangasniemi, et al.
International Journal of Cancer|June 2, 2011
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumorsSari Pesonen, Iulia Diaconu, Vincenzo Cerullo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 24, 2024
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokineSaru Basnet, Mirte Van der Heijden, Dafne C A Quixabeira, et al.
Molecular Therapy Oncolytics|April 24, 2020
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid TumorsVictor Cervera-Carrascon, Dafne C A Quixabeira, Riikka Havunen, et al.
Molecular Therapy. Oncology|July 1, 2025
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinomaVictor Arias, Tatiana V Kudling, James H A Clubb, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Molecular Therapy Oncolytics|January 26, 2023
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumorsSaru Basnet, Joao M Santos, Dafne C A Quixabeira, et al.
Frontiers in Immunology|August 9, 2021
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1Victor Cervera-Carrascon, Dafne C A Quixabeira, Joao M Santos, et al.
International Journal of Cancer|August 13, 2009
Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiationMaria Rajecki, Taija af Hällström, Tanja Hakkarainen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumorsPetri Nokisalmi, Sari Pesonen, Sophie Escutenaire, et al.
British Journal of Cancer|December 8, 2022
Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinomaAstrid Murumägi, Daniela Ungureanu, Suleiman Khan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 16, 2011
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirusVincenzo Cerullo, Iulia Diaconu, Lotta Kangasniemi, et al.
International Journal of Cancer|June 2, 2011
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumorsSari Pesonen, Iulia Diaconu, Vincenzo Cerullo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 24, 2024
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokineSaru Basnet, Mirte Van der Heijden, Dafne C A Quixabeira, et al.
Molecular Therapy Oncolytics|April 24, 2020
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid TumorsVictor Cervera-Carrascon, Dafne C A Quixabeira, Riikka Havunen, et al.
Molecular Therapy. Oncology|July 1, 2025
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinomaVictor Arias, Tatiana V Kudling, James H A Clubb, et al.
Pageof 13